Q4 2022
Released Feb 21, 2023, after the close
10-K filed Feb 21, 2023, 52 days after period end · 0001562762-23-000048
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$274.50M$274.50M derived+9.8% vs Q4 2021+8.0% vs Q3 2022
Net Income$50.06M$50.06M derived+231.4% vs Q4 2021+5.6% vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$203,907,000+8.3%
Operating Incomederived$54,028,000+196.9%
Operating Cash Flowderived$63,975,000−16.1%
Free Cash Flowderived$45,635,000−22.9%
Margins · derived
Gross margin74.3%−1.0 pt vs Q4 2021
Operating margin19.7%+12.4 pt vs Q4 2021
Net margin18.2%+12.2 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $274.50M | $250.02M | $233.45M | $211.67M |
| Net Income | $50.06M | $15.11M | $52.96M | $45.53M |
| EPS Diluted | — | — | $0.52 | $0.44 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Globus Medical Inc · CIK 1237831 · Engraved from SEC EDGAR